Compare IOT & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOT | NTRA |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8B | 27.0B |
| IPO Year | 2021 | 2015 |
| Metric | IOT | NTRA |
|---|---|---|
| Price | $45.30 | $244.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $49.90 | ★ $227.69 |
| AVG Volume (30 Days) | ★ 5.4M | 1.7M |
| Earning Date | 12-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,520,629,000.00 | ★ $2,116,676,000.00 |
| Revenue This Year | $27.68 | $32.77 |
| Revenue Next Year | $20.63 | $16.51 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 28.96 | ★ 38.17 |
| 52 Week Low | $31.40 | $125.38 |
| 52 Week High | $61.90 | $245.59 |
| Indicator | IOT | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 73.46 | 80.03 |
| Support Level | $36.88 | $233.67 |
| Resistance Level | $38.47 | $240.18 |
| Average True Range (ATR) | 1.85 | 7.39 |
| MACD | 0.72 | 0.68 |
| Stochastic Oscillator | 82.90 | 97.49 |
Samsara Inc provides an end-to-end solution for operations. The company's Connected Operations Platform consolidates data from its IoT devices and a growing ecosystem of connected assets and third-party systems, and makes it easy for organizations to access, analyze, and act on data insights using its cloud dashboard, custom alerts and reports, mobile apps, and workflows.. The company derives almost all of its revenue from subscription services. Geographically, it derives a majority of its revenue from the United States. The company's customers ranges from small and medium-sized businesses to state and local governments.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.